COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03420430
Expanded Access Status : No longer available
First Posted : February 5, 2018
Last Update Posted : August 1, 2019
Information provided by (Responsible Party):
Genelux Corporation

Brief Summary:
GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.

Condition or disease Intervention/treatment
Advanced Stage Cancer (Solid Tumor Disease for 4 Patients) Acute Myeloid Leukemia (6 Patients) Biological: GL-ONC1

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
Official Title: Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Diagnosis of advanced cancers with no standard of care option for treatment.
  • Willing and able to provide written, signed informed consent.
  • Use of adequate contraception.
  • Negative pregnancy test.

Exclusion Criteria:

  • Have not recovered from severe adverse events from prior therapy.
  • Major surgery occurred within 28 days prior to treatment.
  • Known immune system disorders such as HIV, or active hepatitis B or C infection.
  • Clinically significant cardiac disease (New York Heart Association Class III or IV).
  • Have received prior therapy with an oncolytic virus of any type.
  • Be receiving antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, ST-246).
  • Have known allergy to ovalbumin or other egg products.
  • Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any unhealed skin wounds or ulcers) as assessed by the treating physician.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03420430

Layout table for location information
United States, Florida
Florida Hospital Cancer Institute
Orlando, Florida, United States, 32804
Sponsors and Collaborators
Genelux Corporation

Additional Information:
Layout table for additonal information
Responsible Party: Genelux Corporation Identifier: NCT03420430    
Other Study ID Numbers: GL-ONC1-021
First Posted: February 5, 2018    Key Record Dates
Last Update Posted: August 1, 2019
Last Verified: January 2018